Skip to main content
1276 search results for:

ASCO 2023 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-05-2024 | Olanzapine | ReviewPaper

    2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients

    Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with various malignancies ranging from early to end stages. In light of frequent changes to the guidelines for optimal management …

  2. Open Access 29-12-2023 | Cytostatic Therapy | Online First

    Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence

    The annual meeting of the American Society of Medical Oncology (ASCO) was held as usual in Chicago, while the meeting focused on gastrointestinal tumors, ASCO-GI, was held in San Francisco. In particular, ASCO-GI included many phase III trials …

  3. Open Access 28-09-2023 | Breast Cancer | ReviewPaper

    Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer

    Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The trial focused on patients with metastatic breast cancer who were …

  4. Open Access 05-12-2023 | Breast Cancer | Online First

    ASCO 2023: highlights in breast cancer

    The 2023 annual meeting of the American Society of Clinical Oncology (ASCO) was again held in June 2023 in Chicago. While not immediately practice changing, results from several interesting studies in the field of breast cancer (BC) were reported.

  5. Open Access 01-12-2023 | Urothelial Cancer | EditorialNotes

    Genitourinary cancers updates: highlights from ASCO 2023

    Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments …

  6. 01-12-2023 | Pancreatic Cancer | EditorialNotes

    ASCO 2023—partnering with patients: the cornerstone of cancer care and research

  7. 13-11-2023 | Pancreatic Cancer | ReviewPaper

    Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

    In this short review, we aim to summarize the essential news and highlights in pancreatic cancer that were presented at ASCO 2023. We focus in particular on primary resectable as well as advanced or metastatic disease. Therefore, the first results …

  8. 17-08-2023 | Glioma | ReviewPaper

    ASCO 2023: new treatment options in CNS tumors

    Invited short review

    Practice-changing therapy for IDH1/2–mutant diffuse glioma was presented at the meeting. Vorasidenib as an oral, brain penetrant, dual inhibitor of mutant IDH1/2 showed very promising results in the phase 3 INDIGO study. Other new treatment …

  9. Open Access 15-09-2023 | Ovarian Cancer | EditorialNotes

    Recent Advances in Gynecological Malignancies: Focus on ASCO 2023

    Gynecological cancers are one of the most common cancers in women irrespective of geography and continue to pose significant challenges to women’s health worldwide. Treatment of gynecologic cancers is becoming more targeted with biomarker-directed …

  10. Open Access 01-12-2023 | Neutropenia | Letter

    Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

    Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor …

  11. Open Access 01-12-2023 | Multiple Myeloma | Erratum

    Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

  12. Open Access 01-12-2023 | Soft Tissue Sarcoma | EditorialNotes

    New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting

    Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immunotherapy could be an effective …

  13. Open Access 01-12-2023 | Multiple Myeloma | Letter

    Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

    Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively …

  14. Open Access 01-12-2023 | Non-Hodgkin Lymphoma | Letter

    CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

    Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20+ NHL cells in clinical …

  15. Open Access 01-12-2023 | Prostate Cancer | Letter

    Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium

    Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably …

  16. Open Access 01-12-2023 | Multiple Myeloma | Letter

    BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting

    Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approval of BCMA-targeted chimeric antigen …

  17. Open Access 01-12-2023 | Multiple Myeloma | Letter

    Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

    Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab …

  18. 08-08-2023 | Events

    A GLOBAL CONGRESS DIGEST ON TARGETED THERAPIES IN B-CELL MALIGNANCIES. Report from the American Society of Clinical Oncology (ASCO) Annual Meeting (hybrid), 2nd-6th June 2023, European Hematology Association (EHA) 2023 Congress (hybrid), 8th-11th June 2023, and the 17th International Conference on Malignant Lymphoma (ICML) 2023 Congress (hybrid), 13th-17th June 2023

  19. 08-08-2023 | Events

    A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the ASCO Hybrid Congress , 2nd – 6th June 2023

  20. 15-06-2023 | Topic page

    2023 ASCO Annual Meeting Coverage

    News and updates from the 2023 ASCO Annual Meeting.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.